Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication
暂无分享,去创建一个
L. Cooper | J. Cooke | J. Isner | J. Regensteiner | M. Creager | W. Hiatt | W. Casscells | A. Hirsch
[1] J. Pearlman,et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. , 2000, Journal of the American College of Cardiology.
[2] A. Quyyumi,et al. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. , 2000, Journal of the American College of Cardiology.
[3] A. Quyyumi,et al. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. , 2000, The American journal of cardiology.
[4] E. Ernst,et al. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. , 2000, The American journal of medicine.
[5] J. Cooke,et al. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar® , 2000 .
[6] C. Diehm,et al. European multicenter study on propionyl-L-carnitine in intermittent claudication. , 1999, Journal of the American College of Cardiology.
[7] D. Dawson,et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. , 1998, Circulation.
[8] R. Oostendorp,et al. The effect of exercises on walking distance of patients with intermittent claudication: a study of randomized clinical trials. , 1998, Physical therapy.
[9] D. Moher,et al. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. , 1996, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[10] Y. Wilson,et al. Treatment of intermittent claudication: the impact on quality of life. , 1995, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[11] J. Regensteiner,et al. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. , 1995, Circulation.
[12] J. Pell,et al. Impact of intermittent claudication on quality of life. The Scottish Vascular Audit Group. , 1995, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[13] R. H. Meier,et al. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. , 1994, Circulation.
[14] L. Kuller,et al. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. , 1993, JAMA.
[15] M. Brughera,et al. Experience with the preclinical assessment of basic fibroblast growth factor (bFGF). , 1992, Toxicology letters.
[16] J. Garb,et al. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. , 1992, Journal of vascular surgery.
[17] E. Barrett-Connor,et al. Pathophysiology and Natural History the Prevalence of Peripheral Arterial Disease in a Defined Population , 2022 .
[18] H. Khaira,et al. Quality of life in patients with intermittent claudication. , 1996, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[19] J. Steiner,et al. Exercise training improves functional status in patients with peripheral arterial disease. , 1996, Journal of vascular surgery.
[20] R. H. Meier,et al. Superiority ofTreadmill Walking Exercise Versus Strength Training forPatients With Peripheral Arterial Disease Implications fortheMechanism oftheTraining Response , 1994 .